JPRN-UMIN000023097已完成2 期
A phase 2 trial of Gemcitabine+Cisplatin+Bevacizumab regimen for the patients with first recurrence or refractory of ovarian clear cell carcinoma KCOG-G1601 - A phase 2 trial of Gemcitabine+Cisplatin+Bevacizumab regimen for the patients with first recurrence or refractory of ovarian clear cell carcinoma KCOG-G1601
Kansai clinical oncology group(KCOG)0 个研究点目标入组 18 人开始时间: 2016年7月11日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 18
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- Female
入选标准
- 未提供
排除标准
- •1)Patient is contraincicated for use in gemcitabine,cisplatin and bevacizumab 2)Patient with uncontrolled heart disease,renal disease and diabetes mellitus 3)Patient with interstitial pneumonia or lung fibrosis 4)Patient with paresis of intestine or ileus 5)Patient with active infection 6)Patient who had chest and abdominal radiation therapy prior to registration 7)Patient with active other malignancy,excluded carcinoma in situ 8)Patient with history of severe drug allergy 9)Patient with obstructive bowel disease,diverticular perforation,intestinal fistula,perforation of the digestive tract,intraperitoneal abscess and Patient with intestinal invasion or ileus confirmed by pelvic examination or CT 10)Patient who have central nerve metastasis with symptom 11)Patient with pregnancy or breast-feeding,Patient who has possibility of pregnancy,notwilling to contraception 12)the following patient 1.Patient with arterial thrombosis or venous thrombosis,included cerebrovascular disorder,stroke,transient ischemic attack or subarachnoid bleeding within 6 months prior to this treatment,but history of arterial thrombosis or venous thrombosis,if control is good,registration is possible. 2.Patient who meets definition of NYHA 2 or has history of myocardial infarction,unstable angina or congestive heart failure 3.Patient with sever arrhythmia who needed medication,excluded atrial fibrillation or paroxysmal supraventricular tachycardia 4.Patient with uncontrolled hypertension(BPs>=150mmHg or BPd>=100mmHg irrespective of treatment) 5.Unhealed wound,ulcer and fracture 6.Patient with positive HBs antigen,HBc antibody or HBs antibody and HPV-DNA>=2.1 log copies/ml 7.HIV infection 13)Patient who received other test drug within 30 days prior to this treatment 14)Attending physician decides to entry inappropriate
研究者
相似试验
进行中（未招募）
不适用
A Phase 1b/2 Study of Gemcitabine-Cisplatin, With or Without LY2275796 Sodium, in Patients with Advanced Stage IIIB or IV Non-Small Cell Lung Cancer - N/AEUCTR2008-001535-35-FREli Lilly and Company175
已完成
不适用
A phase II trial of gemcitabine plus carboplatin in advanced transitional cell carcinoma of the urotheliumCancerISRCTN88259320School of Medicine, Zhejiang University (China)39
进行中（未招募）
1 期
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-FRsanofi-aventis recherche & développement105
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550(BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IV.MedDRA version: 12.1Level: LLTClassification code 10029522Term: Non-small cell lung cancer stage IVEUCTR2009-017270-21-DEsanofi-aventis recherche & développement
进行中（未招募）
不适用
Randomized phase 2 study of gemcitabine/cisplatin with or without SAR240550 (BSI-201), a PARP1 inhibitor, in patients with stage IV non-small cell lung canceron-small cell lung cancer stage IVMedDRA version: 14.0Level: PTClassification code 10029522Term: Non-small cell lung cancer stage IVSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2009-017270-21-ITsanofi-aventis recherche & de'veloppement105